5-(bromomethyl)benzofuroxan | 175609-21-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶二唑类
• 英文名称: 5-(bromomethyl)benzofuroxan
• 英文别名: 5-bromomethylbenzofuroxan；5-bromomethylbenzofuroxane；5-(bromomethyl)-1-oxido-2,1,3-benzoxadiazol-1-ium
• CAS: 175609-21-9
• 化学式: C₇H₅BrN₂O₂
• 分子量: 229.033
• InChiKey: FUGGAZYOVMKPSP-UHFFFAOYSA-N

物化性质

• 熔点：
  73-74 °C
• 沸点：
  335.3±34.0 °C(Predicted)
• 密度：
  1.90±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  51.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(bromomethyl)benzofuroxan 在 manganese(IV) oxide 、 水 、 calcium carbonate 作用下， 以 1,4-二氧六环 、 氯仿 为溶剂， 反应 5.0h， 生成 2,1,3-苯噁二唑-5-甲醛 1-氧化物
  参考文献：
  名称：

  Benzofurazanyl- and benzofuroxanyl-1,4-dihydropyridines: synthesis, structure and calcium entry blocker activity

  摘要：

  The synthesis, structural characterization and calcium blocking activity of a series of benzofurazanyl-1,4-dihydropyridines (18 and 19) and benzofuroxanyl analogues (20 and 21) are reported. H-1-NMR showed that all the benzofuroxan derivatives exist in solution as tautomeric mixtures. The predominant tautomeric form in solution of the derivative 20 (dimethyl 1,4-dihydro-2,6-dimethyl-4-(4-benzofuroxanyl)-3,5-pyridinedicarboxylate) is also the one preferred in the solid state as shown by X-ray analysis. The conformation in the solid state of the benzofurazanyl analogue is also reported. Calcium entry blocker activity of the dihydropyridine derivatives 18-21 has been evaluated in isolated rabbit basilar artery as relaxation of calcium-induced contractions in high K+-depolarizing solution. All the compounds displayed high potency. The activity of benzofurazan derivatives was not changed by the N-oxidation. The two most active compounds 18 and 20 were as potent as Nifedipine.

  DOI：

  10.1016/s0223-5234(96)80001-8
• 作为产物：
  描述：

  5-甲基苯并呋喃-1-氧化物 在 N-溴代丁二酰亚胺(NBS) 、 过氧化苯甲酰 作用下， 以 四氯化碳 为溶剂， 反应 5.0h， 以85%的产率得到5-(bromomethyl)benzofuroxan
  参考文献：
  名称：

  新型的含苯并呋喃类化合物的一氧化氮释放双氯芬酸衍生物的合成和药理学表征

  摘要：

  制备了1-氧-苯并[1,2,5]恶二唑-5-基甲基[2-（2,6-二氯-苯基氨基）-苯基]-乙酸酯，一种新的双氯芬酸衍生物，其结构中带有苯并呋喃基杂环部分双氯芬酸钠和5-溴甲基-苯并[1,2,5]恶二唑1-氧化物的反应。这种修饰的双氯芬酸的药理学特性与其体外和体内测定的母体化合物保持相似的抗炎活性。尽管抑制了前列腺素E 2的胃内含量，但用该修饰化合物未观察到天然双氯芬酸的致溃疡性质。更好的胃耐受性似乎与一氧化氮释放能力有关。

  DOI：

  10.1016/j.ejmech.2010.02.034

文献信息

• Synthesis and some properties of 2 H -benzimidazole 1,3-dioxides
  作者：Elena Chugunova、Vladimir Samsonov、Tatiana Gerasimova、Tatiana Rybalova、Irina Bagryanskaya

  DOI：10.1016/j.tet.2015.03.096

  日期：2015.9

  The synthesis of novel 2H-benzimidazole 1,3-dioxides on the basis of benzofuroxans interaction with alcohols in acids is described. The formation of a stable secondary carbocation from alcohol is necessary for formation of 2H-benzimidazole 1,3-dioxide while substituents in benzofuroxans don't prevent the reaction. Under heating 2H-benzimidazole 1,3-dioxides are rearranged to 3H-[2,1,4]benzoxadiazine

  描述了基于苯并呋喃类与酸中的醇相互作用的新型2 H-苯并咪唑1,3-二氧化物的合成。由醇形成稳定的仲碳阳离子对于形成2 H-苯并咪唑1,3-二氧化物是必要的，而苯并呋喃类中的取代基不会阻止反应。在加热下，将2 H-苯并咪唑1，3-二氧化物重排为3 H- [2,1,4]苯并恶二嗪4-氧化物，其稳定性取决于芳环中的取代基。在辐射下，恶二嗪被转化回2 H-苯并咪唑1，3-二氧化物。
• [EN] DRUGS DERIVED FROM DICLOFENAC CONTAINING NO-DONOR HETEROCYCLES, COMPOSITION AND METHOD OF INFLAMMATION TREATMENT<br/>[FR] MEDICAMENTS DERIVES DU DICLOFENAC, CONTENANT DES HETEROCYCLES DONNEURS DE NO, COMPOSITION ET METHODE DE TRAITEMENT DES INFLAMMATIONS
  申请人：CMAX OTIMIZACAO DE RESULTADOS

  公开号：WO2006042387A1

  公开（公告）日：2006-04-27

  The present invention refers to drugs resulting from the pharmaceutical substance diclofenac, relative to the formula. The invention further refers to a pharmaceutical composition, which involves the said drugs and a pharmaceutically adequate vehicle. It is also described a method for the treatment of inflammation through the administration of the new drugs in patients with gastric problems or subjected to long-term treatments.

  本发明涉及与制药物质双氯芬酸有关的药物，相对于该化学式。该发明还涉及一种制药组合物，其中包括所述药物和药学上适当的载体。还描述了一种通过在患有胃部问题或接受长期治疗的患者中施用新药物来治疗炎症的方法。
• Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors
  申请人：Capraro Hans-Georg

  公开号：US20080261973A1

  公开（公告）日：2008-10-23

  The invention relates to sulphonamidoanilines of formula I, wherein A is N or CH, W, X, Y and Z are N or CH under the proviso that at least one of the three symbols W, X and Y represent CH, R 1 represents NR 4 R 5 or OR 4 , wherein R 4 represents optionally substituted alkyl, optionally substituted cycloalkyl optionally comprising one or two nitrogen or oxygen atoms, or substituted aryl, and R 5 represents hydrogen or unsubstituted or substituted alky, or R 4 and R 5 together with the nitrogen to which they are attached represent an optionally substituted five- or six-membered nitrogen containing monocyclic ring, an optionally substituted nitrogen containing fully saturated bicyclic ring, or an spirocyclic fully saturated ring system containing one or two nitrogen atoms, R 2 is hydrogen, lower alkenyl or alkyl, R 3 is alkyl which is unsubstituted or mono-, di- or trisubstituted by halogen; alkenyl or aryl, and their salts; processes for their preparation, their application in the treatment of the human or animal body, the use thereof—alone or in combination with one or more other pharmaceutically active compounds—for the treatment of diseases, a method for the treatment of such a disease and the use of such a compound—alone or in combination with one or more other pharmaceutically active compounds—for the manufacture of a pharmaceutical preparation for the treatment of a proliferative disease.

  本发明涉及式I的磺酰胺苯胺，其中A为N或CH，W、X、Y和Z为N或CH，但至少三个符号W、X和Y中的一个代表CH，R1代表NR4R5或OR4，其中R4代表可选取代的烷基，可选取代的环烷基，可包含一个或两个氮或氧原子的取代芳基；R5代表氢或未取代或取代的烷基，或R4和R5连同它们所连接的氮表示一个可选取代的五元或六元含氮单环环，一个可选取代的含氮完全饱和的双环环，或一个含有一或两个氮原子的螺环完全饱和环系统，R2为氢、低碳烯基或烷基，R3为未取代或单、二、三取代的卤素的烷基、烯基或芳基，以及它们的盐；它们的制备方法，它们在治疗人体或动物体中的应用，使用它们-独自或与一个或多个其他药理活性化合物结合-治疗疾病的方法，以及使用这种化合物-独自或与一个或多个其他药理活性化合物结合-制造治疗增殖性疾病的药物制剂。
• Drugs Derived from Diclofenac Containing No-Donor Heterocycles, Composition and Method of Inflammation Treatment
  申请人：Pedrazzoli Jose

  公开号：US20080114038A1

  公开（公告）日：2008-05-15

  The present invention refers to drugs resulting from the pharmaceutical substance diclofenac, relative to the formula. The invention further refers to a pharmaceutical composition, which involves the said drugs and a pharmaceutically adequate vehicle. It is also described a method for the treatment of inflammation through the administration of the new drugs in patients with gastric problems or subjected to long-term treatments.

  本发明涉及与药物成分二氯芬酸相关的药物，相对于该化学式。该发明进一步涉及一种药物组合物，其中包括所述药物和药学上适当的载体。还描述了一种治疗炎症的方法，通过向胃部有问题或长期接受治疗的患者施用新药物。
• WO2007/71393
  申请人：——

  公开号：——

  公开（公告）日：——